Development Level

Tbio 120 | 10,625
Tdark 27 | 7,003
Tchem 15 | 1,890
Tclin 1 | 602

IMPC Term

preweaning lethality, complete... 12 | 633
decreased circulating choleste... 6 | 85
decreased circulating HDL chol... 5 | 77
embryonic lethality prior to t... 5 | 187
decreased body weight 4 | 174
decreased circulating LDL chol... 4 | 37
decreased caudal vertebrae num... 3 | 49
decreased circulating alanine ... 3 | 53
decreased total body fat amoun... 3 | 186
abnormal lens morphology 2 | 73
decreased circulating free fat... 2 | 39
decreased lactate dehydrogenas... 2 | 14
decreased lumbar vertebrae num... 2 | 62
decreased rib number 2 | 59
decreased startle reflex 2 | 48
embryonic lethality prior to o... 2 | 148
hydrometra 2 | 13
increased hematocrit 2 | 36
increased mean corpuscular hem... 2 | 93
increased sacral vertebrae num... 2 | 62
abnormal behavior 1 | 226
abnormal embryo size 1 | 112
abnormal eye morphology 1 | 38
abnormal gait 1 | 51
abnormal heart morphology 1 | 51
abnormal hindbrain development 1 | 24
abnormal kidney morphology 1 | 30
abnormal midbrain development 1 | 22
abnormal neural tube closure 1 | 37
abnormal retina morphology 1 | 100
abnormal retinal pigmentation 1 | 61
abnormal sacral vertebrae morp... 1 | 5
abnormal skin condition 1 | 6
abnormal testis morphology 1 | 30
abnormal vibrissa morphology 1 | 17
absent vibrissae 1 | 14
cataract 1 | 26
decreased CD11b-low dendritic ... 1 | 3
decreased CD4-positive NK T ce... 1 | 4
decreased CD8-positive, alpha-... 1 | 26
decreased CD8-positive, naive ... 1 | 5
decreased KLRG1-positive NK ce... 1 | 9
decreased Ly6C-positive immatu... 1 | 4
decreased Ly6C-positive mature... 1 | 4
decreased NK T cell number 1 | 28
decreased NK cell number 1 | 16
decreased T cell number 1 | 31
decreased blood urea nitrogen ... 1 | 31
decreased circulating alkaline... 1 | 41
decreased circulating aspartat... 1 | 27
decreased circulating chloride... 1 | 32
decreased circulating creatini... 1 | 31
decreased circulating serum al... 1 | 79
decreased circulating sodium l... 1 | 18
decreased circulating total pr... 1 | 41
decreased circulating triglyce... 1 | 83
decreased effector memory CD4-... 1 | 6
decreased effector memory CD8-... 1 | 24
decreased fasted circulating g... 1 | 49
decreased gamma-delta T cell n... 1 | 18
decreased grip strength 1 | 123
decreased hematocrit 1 | 25
decreased marginal zone B cell... 1 | 1
decreased marginal zone precur... 1 | 1
decreased memory-marker CD4-po... 1 | 4
enlarged heart 1 | 111
enlarged heart atrium 1 | 2
hydrops fetalis 1 | 22
hypoactivity 1 | 89
immune system phenotype 1 | 17
increased CD11b-high dendritic... 1 | 5
increased CD4-negative NK T ce... 1 | 4
increased CD4-positive, alpha ... 1 | 15
increased CD5-positive Ly6C-po... 1 | 4
increased KLRG1-positive CD4-p... 1 | 3
increased KLRG1-positive T-hel... 1 | 2
increased Ly6C high monocyte n... 1 | 12
increased blood urea nitrogen ... 1 | 44
increased circulating alkaline... 1 | 119
increased circulating creatini... 1 | 29
increased circulating free fat... 1 | 17
increased circulating triglyce... 1 | 24
increased effector memory T-he... 1 | 5
increased fasted circulating g... 1 | 68
increased follicular B cell nu... 1 | 1
increased mean corpuscular vol... 1 | 91
increased plasma cell number 1 | 5
short tibia 1 | 82
small testis 1 | 37
straub tail 1 | 26
thrombocytosis 1 | 23

Disease

ovarian cancer 105 | 8,484
osteosarcoma 88 | 7,933
glioblastoma 70 | 5,572
psoriasis 57 | 6,685
medulloblastoma, large-cell 56 | 6,234
atypical teratoid / rhabdoid tumor 50 | 4,369
lung cancer 46 | 4,466
intraductal papillary-mucinous adenoma (IPMA) 37 | 2,956
intraductal papillary-mucinous neoplasm (IPMN) 34 | 3,289
lung adenocarcinoma 33 | 2,713
intraductal papillary-mucinous carcinoma (IPMC) 32 | 2,988
malignant mesothelioma 31 | 3,162
Multiple myeloma 30 | 1,327
pilocytic astrocytoma 30 | 3,086
pancreatic ductal adenocarcinoma liver metastasis 29 | 1,795
Breast cancer 28 | 3,094
ependymoma 28 | 2,514
invasive ductal carcinoma 28 | 2,950
primitive neuroectodermal tumor 28 | 3,031
non-small cell lung cancer 27 | 2,798
pediatric high grade glioma 26 | 2,712
Carcinoma 25 | 2,147
lung carcinoma 25 | 2,844
pancreatic cancer 25 | 2,300
oligodendroglioma 24 | 2,849
diabetes mellitus 22 | 1,663
Pick disease 20 | 1,893
acute quadriplegic myopathy 20 | 1,157
ulcerative colitis 20 | 2,087
adult high grade glioma 19 | 2,148
astrocytic glioma 19 | 2,241
group 4 medulloblastoma 19 | 1,875
astrocytoma 17 | 1,493
breast carcinoma 17 | 1,614
cystic fibrosis 17 | 1,665
non primary Sjogren syndrome sicca 17 | 840
pituitary cancer 17 | 1,972
Cancer 16 | 2,346
Rheumatoid Arthritis 16 | 1,160
posterior fossa group A ependymoma 16 | 1,511
dermatomyositis 15 | 933
interstitial cystitis 15 | 2,299
medulloblastoma 15 | 1,524
sonic hedgehog group medulloblastoma 15 | 1,482
subependymal giant cell astrocytoma 15 | 2,287
cutaneous lupus erythematosus 14 | 1,056
group 3 medulloblastoma 14 | 2,254
spina bifida 14 | 1,064
tuberculosis 14 | 1,557
tuberculosis and treatment for 6 months 14 | 686
hepatocellular carcinoma 13 | 532
juvenile dermatomyositis 13 | 1,189
posterior fossa group B ependymoma 13 | 1,530
active Crohn's disease 12 | 918
pancreatic carcinoma 12 | 567
acute myeloid leukemia 11 | 780
esophageal adenocarcinoma 11 | 737
colon cancer 10 | 1,475
Duchenne muscular dystrophy 9 | 602
Waldenstrons macroglobulinemia 9 | 765
adrenocortical carcinoma 9 | 1,427
primary pancreatic ductal adenocarcinoma 9 | 1,271
Congenital disorder of glycosylation 8 | 53
Intellectual disability 8 | 573
aldosterone-producing adenoma 8 | 664
autosomal dominant Emery-Dreifuss muscular dystrophy 8 | 499
ductal carcinoma in situ 8 | 1,745
gastric cancer 8 | 430
primary Sjogren syndrome 8 | 789
Bipolar Disorder 7 | 266
atypical teratoid/rhabdoid tumor 7 | 1,095
mucosa-associated lymphoid tissue lymphoma 7 | 480
Amyotrophic Lateral Sclerosis 6 | 431
Congenital dyserythropoietic anemia 6 | 17
Down syndrome 6 | 548
Endometriosis 6 | 535
Polycystic Ovary Syndrome 6 | 332
Schizophrenia 6 | 501
gastric carcinoma 6 | 832
nephrosclerosis 6 | 329
tuberculosis and treatment for 3 months 6 | 327
Anemia 5 | 252
Barrett's esophagus 5 | 183
Heart disease 5 | 279
IGA Glomerulonephritis 5 | 454
Neurodegenerative disease 5 | 383
Obesity 5 | 616
Prostatic Neoplasms 5 | 471
Stomach Neoplasms 5 | 282
Vascular disease 5 | 281
fibroadenoma 5 | 557
hereditary spastic paraplegia 5 | 313
inflammatory breast cancer 5 | 404
nasopharyngeal carcinoma 5 | 1,056
non-small cell lung carcinoma 5 | 413
Alzheimer's disease 4 | 644
Atopic dermatitis 4 | 944
Hypersensitivity reaction type II disease 4 | 235
Myocardial Ischemia 4 | 169
chronic rhinosinusitis 4 | 512

Tissue

Cardiovascular System 163 | 17,958
Digestive Tract 163 | 18,473
Endocrine System 163 | 18,512
Female tissues 163 | 18,647
Liver and Pancreas 163 | 18,136
Male tissues 163 | 17,969
Nervous System 163 | 18,561
Urinary Tract 163 | 18,444
Blood and immune system 162 | 17,995
Respiratory system 162 | 17,484
Skin and soft tissues 162 | 18,115

Target Family

Non-IDG 114 | 11,971
Enzyme 46 | 4,146
Ion Channel 1 | 341
Kinase 1 | 634
Transcription Factor 1 | 1,400

Reactome Pathway

Transport to the Golgi and sub... 163 | 163
Signal Transduction 2,516 | 2,516
Immune System 2,184 | 2,184
Metabolism 2,132 | 2,132
Gene Expression 1,755 | 1,755
Metabolism of proteins 1,545 | 1,545
Innate Immune System 1,376 | 1,376
Signaling by GPCR 1,330 | 1,330
Developmental Biology 1,029 | 1,029
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,005 | 1,005
Adaptive Immune System 939 | 939
Disease 856 | 856
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 804 | 804
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 669 | 669
Membrane Trafficking 608 | 608
Cell Cycle 573 | 573
Axon guidance 542 | 542
Neutrophil degranulation 542 | 542
Signaling by Interleukins 501 | 501
Cell Cycle, Mitotic 471 | 471
Signalling by NGF 468 | 468
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 436 | 436
Class I MHC mediated antigen p... 431 | 431
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 424 | 424
Cellular responses to stress 416 | 416
DAP12 interactions 410 | 410
Infectious disease 392 | 392
NGF signalling via TRKA from t... 379 | 379
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 368 | 368
Diseases of signal transductio... 360 | 360
Signaling by EGFR 356 | 356
Transcriptional Regulation by ... 356 | 356
Metabolism of amino acids and ... 354 | 354
DAP12 signaling 347 | 347
Downstream signal transduction 344 | 344
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 330 | 330
Signaling by SCF-KIT 328 | 328
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 322 | 322
FCERI mediated MAPK activation 317 | 317
Signaling by Insulin receptor 313 | 313
Antigen processing: Ubiquitina... 302 | 302
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 291 | 291
Signaling by Wnt 291 | 291
IGF1R signaling cascade 290 | 290
IRS-related events triggered b... 290 | 290
Insulin receptor signalling ca... 289 | 289
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 286 | 286
MAPK family signaling cascades 284 | 284
Signaling by the B Cell Recept... 283 | 283
Asparagine N-linked glycosylat... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 278 | 278
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 269 | 269
M Phase 267 | 267
Interleukin-3, 5 and GM-CSF si... 263 | 263
RET signaling 262 | 262
Signalling to ERKs 255 | 255
Interleukin-2 signaling 254 | 254
Immunoregulatory interactions ... 252 | 252
VEGFR2 mediated cell prolifera... 250 | 250
RHO GTPase Effectors 249 | 249
Signalling to RAS 248 | 248
Interleukin receptor SHC signa... 247 | 247
G alpha (i) signalling events 245 | 245
Signaling by Leptin 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Prolonged ERK activation event... 244 | 244
MAPK1/MAPK3 signaling 243 | 243
Frs2-mediated activation 242 | 242
HIV Infection 242 | 242
ARMS-mediated activation 241 | 241
Signalling to p38 via RIT and ... 241 | 241
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 237 | 237
RAF/MAP kinase cascade 237 | 237
SHC1 events in EGFR signaling 237 | 237
SOS-mediated signalling 237 | 237
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Ub-specific processing proteas... 203 | 203

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Beta-galactoside alpha-2,6-sialyltransferase 1 ST6GAL1 Tchem Enzyme -2.37851 255.2 269
Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A MGAT5 Tchem Enzyme -2.07315 133.7 104
Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase MGAT3 Tchem Enzyme -1.22408 15.8 139
Vesicular integral-membrane protein VIP36 LMAN2 Tbio Non-IDG -1.35463 24.9 101
Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B MGAT4B Tdark Enzyme -0.75856 4.88 37
Insulin INS Tbio Non-IDG -5.14691 141255.4 1549
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A ANKRD28 Tbio Enzyme -0.56847 4.64 67
Dynein light chain 1, cytoplasmic DYNLL1 Tbio Non-IDG -2.65303 525.6 142
BET1-like protein BET1L Tbio Non-IDG 0.12 0.65 16
Golgin subfamily A member 2 GOLGA2 Tbio Non-IDG -1.94177 80.5 168